The Pulmonary
Dispatch
Local time07 . 00
A weekly pulmonology literature update for physicians. New papers by 44 leading experts in pulmonary hypertension, interstitial lung disease and IPF, severe asthma, COPD, bronchiectasis, chronic cough and CPET, each with the key numbers from its abstract.
5 highlights · 13 papers in all
01Bronchiectasis
Chalmers JD · Shteinberg M (last author)
83 women, 121 pregnancies. Assisted reproduction in 32.1% of pregnancies, far more often in PCD (48.5% vs 8.7%). Lung function stayed stable during and after pregnancy; exacerbations occurred in 58.6%.
02PH / CTEPH
Hoeper MM · Humbert M (last author)
CT angiography as the reference for locating the bleeding source, severity-tiered management up to bronchial artery embolisation, and long-term follow-up for recurrence.
03Asthma
Brusselle G
Post hoc analysis of a 2-year prospective study in adults starting mepolizumab, split by allergic / omalizumab-eligible phenotype and type 2 biomarkers (eosinophils, IgE, FeNO). OCS use fell across phenotypes.
04Pneumonitis
Editor's pick · Yanagihara T et al., Fukuoka University
First reported pneumonitis on nerandomilast. A 33-year-old with unclassifiable IIP developed fever, hypoxaemia and new bilateral consolidation and ground-glass opacities 9 days after starting the drug; it recurred the day after a reduced-dose rechallenge and resolved again on withdrawal. Worth remembering as the drug enters practice.
05ILD
Richeldi L
158 patients with PPF across Italian centres. 19% had at least one indirect echo sign of RV afterload, most often a short RVOT acceleration time. Only male sex stayed independent on multivariable analysis.
None of this week's highlights are in this topic.
8 papers
J Infect Dis ·
Sitbon O · Humbert M
20 HIV-PAH patients against 20 HIV controls. Anti-AnxA5 in 55% vs 0% (P<0.001), anti-14-3-3ε in 35% vs 5%, a pattern close to connective-tissue-disease PAH. A research marker pending prospective validation.
J Allergy Clin Immunol ·
Papi A
Nasal RNA-seq from 361 patients and 57 controls (ATLANTIS): 1,731 genes vary by season (FDR<0.05), replicated in PIAMA. Adjusting for sampling season sharpens asthma gene detection.
Tuberc Respir Dis ·
Chalmers JD (last author)
Case-based walk through the 2025 ERS guideline: individual risk assessment rather than exacerbation count alone, and long-term macrolides as first-line in a broad group regardless of Pseudomonas.
Eur Respir J · Editorial · · Title only, no abstract
Busse WW · Jackson DJ
Editorial on whether spirometry is needed to judge biologic response.
JAMA · · Title only, no abstract
Wechsler ME (last author)
Maintenance rituximab in EGPA; possibly a companion commentary.
Eur Respir J · Letter · · Title only, no abstract
Sitbon O · Humbert M
Circulating activin A, FSTL3 and BMP9 in asymptomatic carriers of a pathogenic variant.
Eur Respir J · Letter · · Title only, no abstract
Maher TM
IPF genetic risk variants evaluated across ancestries.
Eur Respir J · Letter · · Title only, no abstract
Cottin V (affiliation to confirm)
Clinical presentation and prognosis compared between chronic beryllium disease and pulmonary sarcoidosis.
Nothing else in this topic this week.
14 papers changing practice this year
N Engl J Med · 2026
Fewer moderate-to-severe exacerbations with IL-33 blockade, including in patients with low blood eosinophils, which opens a biologic option beyond the type 2 phenotype. Not yet approved.
N Engl J Med · 2025
1,177 patients, 78% on background nintedanib or pirfenidone. FVC change at 52 weeks −114.7 mL with 18 mg bid vs −183.5 mL with placebo (difference 68.8 mL, P<0.001). Diarrhoea 41% vs 16%. First new IPF drug in over a decade.
N Engl J Med · 2026
593 patients, 75% on background antifibrotics. FVC difference 95.6 mL at 52 weeks (P<0.001); clinical worsening 27.2% vs 39.0% (HR 0.71). No effect on time to acute exacerbation. Cough 48% vs 24%, discontinuation 34% vs 25%.
Lancet Respir Med · 2026
4,311 patients uncontrolled on medium- or high-dose ICS-LABA. Trough FEV1 +76 mL vs budesonide-formoterol; severe exacerbations IRR 0.86 (vs Aerosphere BFF) and 0.82 (vs Symbicort). Benefit held regardless of recent exacerbation history.
N Engl J Med · 2025
1,721 patients. Annualised exacerbation rate 1.02 (10 mg) and 1.04 (25 mg) vs 1.29 with placebo (rate ratios 0.79 and 0.81). First therapy approved specifically for bronchiectasis.
N Engl J Med · 2025
172 patients in WHO FC III–IV, REVEAL Lite 2 ≥9, on maximal background therapy. Death, transplant or PAH hospitalisation 17.4% vs 54.7% (HR 0.24). Stopped early for efficacy.
Am J Respir Crit Care Med · 2026
Target-trial emulation in 2,270 patients. No survival or FVC-trajectory benefit in any subtype; worse 3-year transplant-free survival in non-IPF IIP (HR 1.38) and fibrotic HP (HR 1.62). Observational; RCTs needed.
CHEST · 2026
Seven PICO-based recommendations. Choice guided by QoL, lung function, exacerbation frequency, maintenance OCS, endotype, biomarkers and comorbidities; no head-to-head data. Consider switching after a poor response at 4–6 months.
Eur Respir J · 2026
150 patients ≥3 months after PE, stepwise CPET, perfusion scan, echo and rest/exercise RHC. Recovery 66%; chronic thromboembolism phenotypes 12%, mostly without PH; CTEPH 2.1%, CTED with exercise PH 3.5%.
CHEST · 2026
4,477 adults with asthma. Smoking cannabis was associated with OCS-treated attacks at one year (OR 1.64, 95% CI 1.12–2.40), with signals for vaping too. Observational.
Am J Respir Crit Care Med · 2026
106 patients with grade 1–2 ICI pneumonitis. Success at 8 weeks 66.7% vs 85.2%; non-inferiority of 3 weeks not shown, exploratory superiority of 6 weeks. Keep the guideline 6-week taper.
Am J Respir Crit Care Med · 2026
100 patients in South Korea. Three-day pulse did not beat a 7-day standard dose: mortality 10% vs 15% at 28 days and 25% vs 30% at 90 days, not significant.
Am J Respir Crit Care Med · 2026
Extends the 2016 AE-IPF definition to all fibrotic ILD: acute event with DAD-pattern imaging or histology. Adds an acute respiratory worsening framework to separate AE from infection, oedema and other causes.
ERJ Open Res · 2026
190 adults with severe eosinophilic asthma. ICS nonadherence in 52% of non-responders vs 22% of responders, with higher FeNO when nonadherent. Read with SHAMAL: on benralizumab, 92% could step ICS down, though not to zero.
No classics in this topic yet.
119 papers · 8 earlier issues
Ann Am Thorac Soc ·
Celli (14th of 51) · Vestbo (45th of 51) · Agusti (9th of 51) · Brusselle (13th of 51)
Using expert consensus, we devised an internationally-supported, proposed definition and work-up for 'severe COPD', accounting for disease heterogeneity. This definition may improve identification of the population and supports a structured evaluation of this often under-recognized and potentially undertreated population.
Eur Respir J ·
Chalmers (80th of 81)
Distinct oral and sputum microbiota profiles were associated with pulmonary function and with neurocognitive and gastrointestinal symptoms in long COVID. Shifts in keystone microbiota taxa linked with inflammation, based on worse health outcomes, suggest a potential role change for lactic acid bacteria, which may be associated with the host immune response.
Rhinology ·
Wechsler (30th of 32)
Over the past decade, biologic therapies targeting key inflammatory pathways have fundamentally transformed the treatment landscape for patients with chronic inflammatory airway diseases. These therapies are now widely approved worldwide and increasingly implemented in routine clinical practice (1).
Am J Respir Cell Mol Biol ·
Wenzel (18th of 23)
Secretor status does not influence mucus plugging or exacerbation outcomes in the SARP-3 cohort, and it does not have significant effects on mucin expression or biophysical properties of airway mucus.
Respir Med ·
Raghu (last)
In this exploratory pilot trial, a modified yoga program was feasible and well tolerated and was associated with improvements in selected patient-reported outcome domains. These findings are hypothesis-generating and warrant evaluation in a larger, adequately powered trial.
ERJ Open Res ·
Humbert (10th of 13) · Sitbon (9th of 13)
Across complementary data sources, there was no evidence of a causal association between exposure to bevacizumab and the development of PAH in adults. However, the effect of bevacizumab as a secondary trigger in predisposed individuals cannot be definitely or completely excluded.
BMJ Open Respir Res ·
Maher (first) · Cottin (last) · Wijsenbeek (5th of 14) · Martinez (2nd of 14)
NCT06003426.
Chin Med J Pulm Crit Care Med ·
Chalmers (2nd of 3)
Bronchiectasis is a chronic airway disease characterized by irreversible bronchial dilatation and substantial clinical heterogeneity. Accumulating evidence from large international observational cohorts has highlighted wide variation in the features of this disease and unmet clinical needs.
J Thorac Dis ·
Agusti (4th of 17) · Halpin (6th of 17) · Chalmers (2nd of 17)
[Abstract not available]
J Allergy Clin Immunol Pract ·
Busse (last)
[Abstract not available]
Chest ·
Cottin (25th of 39)
In EGPA patients with persistent respiratory manifestations after mepolizumab failure, switching to benralizumab could represent a valuable option, improving lung function and reducing glucocorticoid use. Further prospective studies are needed to optimize sequencing and patient selection.
Eur Respir J ·
Humbert (3rd of 4)
[Abstract not available]
Am J Respir Crit Care Med ·
Brusselle (last)
The Global Initiative for Asthma (GINA) Strategy Report provides a comprehensive, annually updated evidence-based approach to asthma diagnosis, assessment, treatment, and prevention across the lifespan. Its central approach is personalized, iterative care based on the Assess-Adjust-Review cycle for both symptom control and reduction of future risk (including severe exacerbations, persistent airflow limitation, and tr
Med Sci Sports Exerc ·
Arena (7th of 11)
A six-month eHealth-guided exercise intervention using AQ was more effective than standard PA advice in improving V̇O2peak and mental HRQoL among physically inactive adults recovering from COVID-19. These findings highlight the potential of AQ as an effective and feasible approach for post-COVID rehabilitation.
Am J Respir Crit Care Med ·
Chalmers (first)
[Abstract not available]
Eur Respir Rev ·
Chalmers (first)
Bronchiectasis (BE) is a heterogeneous lung disease characterised by chronic neutrophilic inflammation. A "vicious vortex" develops through the interactions between neutrophilic inflammation, infection and impaired mucociliary clearance, leading to progressive structural lung damage and worsening lung function.
J Clin Invest ·
Wenzel (last)
Type 2 (T2) inflammation is a defining feature of asthma and associated with epithelial dysfunction, including goblet cell metaplasia and ciliary loss. Here, we investigated whether T2 inflammation and associated 15 lipoxygenase-1 (15LO1) activity alters mitochondrial metabolism in airway epithelial cells (AECs) and contributes to disease pathophysiology.
Respir Med ·
Brusselle (2nd of 8)
Early escalation to SITT in COPD may result in more durable sustained clinical benefits compared with later intervention, reducing exacerbations and maintaining disease stability and control up to 12 months.
Chest ·
Pavord (6th of 8) · Jackson (7th of 8) · Chung (5th of 8)
Over two-thirds of biologic-eligible patients improved with standard care alone. Chronic-frequent exacerbators had higher blood eosinophil counts, even years before meeting biologic criteria, suggesting a distinct disease phenotype.
Allergy Asthma Immunol Res ·
Chung (23th of 25)
We discovered and validated 3 B-TACs, with B-TAC2 displaying a mixed T2-high and non-T2 phenotype, suggesting a potential reduction in responsiveness to biologic treatments. These findings provide molecular insights that may guide the development of personalized treatment strategies for asthma.
J Allergy Clin Immunol ·
Busse (12th of 13)
The NIH-sponsored Urban Environment and Childhood Asthma (URECA) study of families in low-income, urban neighborhoods has provided important insights in this population but has a limited capacity to investigate risk factors across broader geographic and sociodemographic settings. To overcome this shortcoming, URECA investigators have shared data with multiple NIH-sponsored birth cohorts and investigators, including t
Am J Respir Cell Mol Biol ·
Ghofrani (22th of 24)
Our study provides evidence that CA9 and 12 are engaged in the pathogenesis of hypoxia and non-hypoxia associated PH and may represent novel therapeutic targets in future.
Am J Respir Crit Care Med ·
Chalmers (8th of 19)
ALIS with MDT was superior to the comparator arm for improving respiratory symptoms and CC in patients newly diagnosed with MACLD.
J Allergy Clin Immunol ·
Jackson (7th of 15)
The structure and function of the airway epithelium are central in protecting against harmful environmental insults and conserving respiratory health; however, epithelial dysfunction can contribute to airway disease. Epithelial health represents a state of equilibrium where the airway epithelial barrier, immune activity and mucociliary dynamics work in concert to maintain tissue integrity and prevent inflammation.
Am J Respir Crit Care Med ·
Raghu (19th of 21)
Among adults with AE-IPF, pulse-dose methylprednisolone did not demonstrate improved 28- or 90-day survival compared with a nonpulse corticosteroid regimen.
Am J Respir Crit Care Med ·
Martinez (8th of 13) · Celli (4th of 13) · Agusti (last) · Wedzicha (12th of 13) · Halpin (7th of 13)
[Abstract not available]
ERJ Open Res ·
Agusti (9th of 14) · Chalmers (12th of 14)
Severe bronchiectasis patients presented an altered blood epigenetic profile, which was influenced by blood neutrophils. These findings suggest that bronchiectasis has systemic implications, especially for the most severely affected patients.
ERJ Open Res ·
Pavord (2nd of 12) · Chalmers (3rd of 12)
Patients with moderate asthma treated with BUD/FORM MART recorded less variation in asthma outcomes and lower rates of exacerbation events than those treated with BUD/FORM maintenance therapy plus SABA, suggesting improved asthma control.
ERJ Open Res ·
Chalmers (15th of 16)
Sputum cathepsin G activity relates to disease severity, disease activity and prognosis in bronchiectasis. High cathepsin G levels are associated with more severe clinical outcomes and could serve as a target for future therapeutic interventions, including dipeptidyl peptidase 1 inhibitors.
ERJ Open Res ·
Humbert (14th of 15) · Sitbon (12th of 15)
In severe PH-COPD, acute pulmonary vasoreactivity is associated with improved long-term survival and a better response to PAH-approved therapies. Further studies are warranted to confirm that acute NO testing may help identify a specific PH-COPD subgroup likely to benefit from PAH-approved treatment.
ERJ Open Res ·
Agusti (10th of 11) · Papi (9th of 11)
Although preterm-born adults with obstructive respiratory disease are aware of their neonatal history, it is seldom integrated into adult respiratory care. Limited patient disclosure, infrequent physician inquiry and lack of structured long-term follow-up likely contribute to this gap.
ERJ Open Res ·
Chalmers (11th of 17)
PEs are increasingly used as the primary outcome in bronchiectasis trials, making accuracy in their identification essential. More rigorous capture of exacerbation symptoms and implementation of a standardised and reproducible decision-making process, supported by an independent adjudication panel, is important for capturing PEs and ensuring the integrity of trial outcomes.
ERJ Open Res ·
Hoeper (8th of 14)
Our data suggest thatmRNA expression is not only significantly reduced in carriers of pathogenicvariants, but also across all other assessed PAH subgroups and in CTEPH, indicating a potential general impairment of BMPR2 signalling.mRNA and BMP10 protein expression in blood may serve as novel biomarkers for disease severity.
Respir Res ·
Hoeper (9th of 12)
ECVexposure increased endothelial permeability and lung edema formation in an angiopoietin/Tie2 dependent manner ex vivo, and susceptibility to LPS stimulation in vitro. We identified the Tie2 activating anti-permeability agent PMC-403 as a potential therapeutic agent of acute lung injury in this context.
Respir Res Clin Pract ·
Neder (first)
[Abstract not available]
ERJ Open Res ·
Chalmers (first) · Shteinberg (2nd of 20)
There is an unmet need for therapies targeting chronic neutrophilic inflammation in bronchiectasis. In the phase II, dose-finding AIRLEAF study, the dipeptidyl peptidase 1 (cathepsin C) inhibitor verducatib (BI 1291583) reduced the pulmonary exacerbation risk in people with bronchiectasis and demonstrated a similar safety profile to placebo; these results support the investigation of verducatib in a phase III study.
Radiology ·
Ryerson (2nd of 11)
This review aims to summarize the key features of the 2025 update of the European Respiratory Society-American Thoracic Society Classification of Interstitial Pneumonias from a radiologic perspective. It highlights the revised terminology, pattern definitions, and conceptual framework, which moves beyond the previous focus on idiopathic interstitial pneumonias toward a broader radiologic-pathologic pattern-based appr
ERJ Open Res ·
Cottin (6th of 8)
The results highlight the relevance of assessing coping strategies in cases of anxiety/depression and suggest that adaptive strategies such as commitment to actions in line with personal values and acceptance should be prioritised.
Am J Respir Crit Care Med ·
Martinez (19th of 24)
One-year progression of CT emphysema subtypes predicted accelerated FEV₁ decline, supporting their potential use as intermediate endpoints in COPD trials.
Chest ·
Hemnes (25th of 26)
Among 252 subjects (81 obstructive, 125 interstitial, 46 non-parenchymal), PA size associated with PH (Q3 vs Q1 OR 4.30 [2.32-8.00] for diameter, 5.66 [2.86-11.18] for PA/A) and mPAP (ρ = 0.516 for diameter, 0.494 for PA/A; p < 0.001) and possessed moderate ability to detect PH (AUC 0.794 for diameter, 0.765 for PA/A). Association between PA/A and mPAP was strongest in non-parenchymal subjects (ρ = 0.750) and weakest
Eur Respir J ·
Wechsler (first)
[Abstract not available]
Eur Respir J ·
Delcroix (10th of 13)
[Abstract not available]
Pulm Ther ·
Busse (last)
In this analysis of a large US claims database, mepolizumab reduced exacerbations and overall disease burden in patients with asthma and concurrent COPD.
Am J Respir Crit Care Med ·
Celli (last) · Wedzicha (first)
[Abstract not available]
Am J Respir Crit Care Med ·
Agusti (5th of 8)
[Abstract not available]
Am J Respir Crit Care Med ·
Flaherty (19th of 22) · Cottin (20th of 22)
Inhaled treprostinil slowed the rate of lung function loss, delayed clinical worsening and IPF exacerbations, and demonstrated benefits in DLCO and quality of life over 52 weeks. The results support the use of inhaled treprostinil in patients with IPF.
Eur Respir Rev ·
Humbert (7th of 13) · Sitbon (6th of 13)
Pulmonary arterial hypertension (PAH) with features of venous and/or capillary involvement, formerly pulmonary veno-occlusive disease (PVOD), represents a rare and severe subset of pulmonary hypertension. While PVOD is typically idiopathic, heritable or drug/toxin-induced, "PVOD-like" features have long been recognised in PAH associated with connective tissue diseases (CTDs), especially systemic sclerosis (SSc).
Prim Health Care Res Dev ·
Halpin (first)
Large-scale quality improvement programmes (QIPs) have diverse factors that may influence their success and can undergo rapid changes throughout their lifecycle. The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) programme has recently been implemented in primary care practices in the UK.
Allergy ·
Chung (19th of 21)
Gut and airway-derived microbiomes appear to play complementary roles in severe asthma. Stool-derived microbial features may reflect systemic inflammatory signals associated with treatment response, whereas airway-derived microbial profiles reflect local airway inflammation.
Am J Respir Crit Care Med ·
Brusselle (8th of 48)
Our study reveals a lower prevalence of biologic therapy among adults with severe asthma who smoke and provides evidence suggesting this practice is unwarranted. Former/current smokers who underwent biologic therapy for one year responded as effectively as never-smokers.
ERJ Open Res ·
Chalmers (27th of 34)
These data do not support the use of HTS or carbocisteine to alter sputum viscoelasticity, inflammatory marker levels or bacterial community composition in patients with bronchiectasis.
ERJ Open Res ·
Halpin (2nd of 16) · Papi (first)
analyses of the AReSVi-006 trial suggest that adjuvanted RSVPreF3 may help prevent RSV-ARI, RSV-LRTD and RSV-related complications in medically stable older adults with underlying medical conditions like COPD and asthma.
ERJ Open Res ·
Humbert (10th of 12) · Sitbon (9th of 12)
https://bit.ly/4wvje3V.
ERJ Open Res ·
Chalmers (11th of 52)
GPPAQ demonstrates internal consistency, with construct and convergent validity in adults 1 year after COVID-19 hospitalisation. GPPAQ effectively identifies inactive individuals to support clinical care; however, its sensitivity suggests under-estimation of activity relative to accelerometry.
Respirology ·
Chung (19th of 20)
CVD is independently associated with worse clinical outcomes across the asthma disease spectrum. These findings support recognition of CVD as an important treatable trait in asthma and highlight the need for integrated cardiopulmonary management.
BMC Pulm Med ·
Hoeper (8th of 9)
After accounting for baseline imbalance in age, BMI, COVID-19 severity, and comorbidities, and after correcting for multiple testing, sex-specific differences persisted for fatigue, anxiety, quality of life, and work productivity impairment, as well as selected lung function parameters. These differences did not change significantly across the 10-month observation period and did not show a significant sex-by-time int
Am J Respir Crit Care Med ·
Wijsenbeek (3rd of 4)
[Abstract not available]
Am J Respir Crit Care Med ·
Raghu (last)
[Abstract not available]
Front Med (Lausanne) ·
Chung (5th of 7)
Residential air pollution exposure across the evaluated pre-recruitment averaging periods was associated with COPD. The nominal HGB PRS-SOinteraction suggests heterogeneity in hematologic responses according to genetic susceptibility, whereas the within-COPD anemia analysis did not show a consistent positive association between ambient air pollution and anemia status.
JHLT Open ·
Humbert (20th of 24) · Sitbon (17th of 24)
Advances in severe PAH management have enabled transplantation in older and more intensively treated patients without compromising short-term outcomes. However, major disparities in access to transplantation persist across PAH aetiologies, underscoring the persistent challenges in advanced PAH management.
BMJ Open ·
Satia (last)
NCT07288528.
J Allergy Clin Immunol Pract ·
Wechsler (4th of 7)
There was no significant increase in risk for the selected adverse outcomes in women exposed to LABAs during pregnancy.
Ther Adv Respir Dis ·
Chalmers (9th of 11) · Shteinberg (8th of 11)
AI software, particularly ChatGPT, provided accurate, comprehensive, and understandable answers to our 15 bronchiectasis-related questions.
Am J Respir Cell Mol Biol ·
Busse (first)
[Abstract not available]
Respir Med ·
Brusselle (6th of 10)
Six clinically interpretable phenotypic subgroups based on smoking history, pulmonary function, and symptoms were identified and externally validated, highlighting the importance of classifying patients based on shared observable characteristics to inform on disease susceptibility and prognosis.
Sci Rep ·
Chung (3rd of 15)
Heat wave burden is rapidly rising and exacerbating human respiratory illnesses. Yet, how to protect human airways, short of deep and sustained reductions in greenhouse gas emissions, remains unclear.
ERJ Open Res ·
Halpin (last)
QuOTE may improve the assessment and tracking of respiratory and sleep symptoms during initiation and ongoing treatment of patients with chronic respiratory disease receiving LTOT. By providing a brief, simple and oxygen therapy-specific tool, QuOTE can facilitate investigation of the clinical impact of LTOT and support more standardised follow-up.
ERJ Open Res ·
Papi (3rd of 10) · Brusselle (4th of 10)
Among patients with asthma that was uncontrolled by an inhaled corticosteroid (ICS)/long-acting β-agonist (LABA) combination prior to study entry, a higher proportion achieved clinical remission by switching to inhaled triple therapy than by continuing ICS/LABA.
ERJ Open Res ·
Papi (3rd of 13) · Jackson (first)
These findings support the use of BFF320 with co-suspension delivery technology in people with inadequately controlled asthma on medium-dose ICS or ICS/LABA.
ERJ Open Res ·
Papi (first) · Jackson (3rd of 13)
These findings support the use of BFF160 twice daily with novel Aerosphere technology for the treatment of people aged 12-80 years with asthma inadequately controlled by low-dose ICS or ICS/LABA.
Ann Am Thorac Soc ·
Raghu (5th of 12)
The IPF-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers.
Med Gas Res ·
Palange (last)
Obstructive sleep apnea is a prevalent sleep-related breathing disorder with recurrent episodes of upper airway collapse during sleep, leading to cyclic blood gas fluctuations. Oxygen, carbon dioxide, and nitric oxide play a crucial role in the pathophysiology.
Respir Res Clin Pract ·
Neder (last) · O'Donnell (3rd of 4)
[Abstract not available]
Am J Respir Crit Care Med ·
Chalmers (25th of 26) · Shteinberg (13th of 26)
PA-abundotypes and interactotypes represent independent traits capturing different dimensions of PA ecology and potentially contributing to observed clinical and treatment heterogeneity in bronchiectasis.
Eur Respir J ·
Humbert (18th of 20) · Sitbon (16th of 20)
Pulmonary hypertension (PH) may complicate a broad range of genetic syndromes beyond the established spectrum of heritable pulmonary arterial hypertension. Although these conditions are individually rare, together they represent an emerging field at the crossroads of developmental biology, vascular medicine, and precision genomics.
Thorax ·
Martinez (10th of 15)
Integrative multi-omics analyses suggest that perturbations to microvascular remodelling contribute to disease severity and progression in IPF. This analysis offers a framework for a precision medicine approach for IPF.
Pulm Circ ·
Kovacs (10th of 13)
Chronic obstructive pulmonary disease (COPD) is frequently associated with pulmonary vascular disease (PVD) yet pulmonary vascular involvement remains underrecognized and incompletely phenotyped. Emerging evidence demonstrates that pulmonary vasculopathy may precede overt emphysema and airflow obstruction, suggesting that vascular remodeling is an early and integral component of COPD pathobiology rather than solely a
Chest ·
Jackson (31th of 142) · Wechsler (17th of 142)
gov.
Eur Respir Rev ·
Satia (first)
Lung function peaks in early adulthood and declines thereafter, even without respiratory disease. Differentiating physiological ageing from pathological trajectories is critical for diagnosis, prognostication and interpretation of clinical trial end-points, particularly in interstitial lung diseases where attenuation of forced vital capacity (FVC) decline is a primary outcome in most trials.
Eur Respir Rev ·
Ryerson (8th of 9)
A wide variety of comorbidities affect clinically encountered patients with IPF, with many having higher prevalence rates than those reported in clinical trial cohorts. This highlights the need for personalised care in the management of IPF.
Allergy ·
Wechsler (first)
Rapid and sustained improvements were more pronounced in patients with type 2-high biomarkers than previously reported in the overall study population.
N Engl J Med ·
Martinez (5th of 28) · Papi (13th of 28)
Among patients with COPD, treatment with tozorakimab resulted in a significantly lower rate of moderate or severe exacerbations than placebo in the cohort of former smokers and in the overall population of current and former smokers.
Eur Respir J ·
Hoeper (23th of 24) · Humbert (3rd of 24) · Vonk Noordegraaf (21th of 24) · Rosenkranz (19th of 24) · Sitbon (20th of 24) · Kovacs (first) · Delcroix (last)
The ERS guidelines on the treatment of PAH provide an updated evidence-based framework for the optimal management of patients with PAH.
Eur Respir J ·
Humbert (last)
The circulating ligands bone morphogenetic protein (BMP)-9 and BMP-10 are emerging as dual regulators of pulmonary and systemic vascular biology. Acting through activin receptor-like kinase 1 (ALK1), BMP receptor type II (BMPRII) and endoglin receptor complexes, they maintain endothelial quiescence and vascular tone under physiological conditions.
Respirology ·
Richeldi (last)
Multidisciplinary discussion remains the cornerstone of ILD diagnosis and management, with recent advances further strengthening the integration of clinical, radiological, pathological, and molecular information. Updated ILD nomenclature and classification better align disease terminology with underlying morphology and pathobiology.
Respirology ·
Ryerson (2nd of 10)
In this registry cohort anchored at enrollment, CTD-ILD had superior transplant-free survival versus IPF, and ILD-GAP provided moderate prognostic accuracy.
ERJ Open Res ·
Neder (last) · O'Donnell (10th of 11)
This study may validate an original framework for investigating dyspnoea using CPET, characterised by continuous assessment of symptom intensity and time course, in light of the rate of dynamic depletion of mechanical-ventilatory reserves.
ERJ Open Res ·
Brusselle (3rd of 6)
Low ASMI was more prevalent in PRISm compared to normal spirometry. PRISm at baseline and smoking were strongly associated with COPD development, with the highest risk in individuals with PRISm and low ASMI, suggesting that low ASMI in PRISm may be a treatable trait requiring clinical attention.
TH Open ·
Vonk Noordegraaf (6th of 11)
Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disorder associated with venous thromboembolism (VTE) and chronic thromboembolic pulmonary hypertension (CTEPH). Current guidelines recommend APS screening in CTEPH patients.
Chest ·
Wechsler (last)
[Abstract not available]
Radiol Cardiothorac Imaging ·
Raghu (10th of 11)
Purpose To determine whether cardiac MRI strain parameters independently predict PET/CT-defined myocardial inflammation in patients with cardiac sarcoidosis (CS). Materials and Methods This retrospective study included patients with definite or probable CS who underwent cardiac MRI and fluorine 18 fluorodeoxyglucose (FDG) PET/CT between January 2010 and October 2022 within 90 days per the Japanese Circulation Society
Ann Am Thorac Soc ·
Martinez (8th of 15)
NCT01969344.
Sci Transl Med ·
Humbert (12th of 19)
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that leads to right heart failure and ultimately death. Therapeutic options targeting the underlying mechanisms of the disease are urgently needed.
ERJ Open Res ·
Halpin (first)
T2 multimorbidities are present in COPD and their prevalence increases with BEC, though they are generally less prevalent than in asthma, suggesting distinct immunopathology.
ERJ Open Res ·
Chung (35th of 45)
We present the first use of electronic healthcare records in UK Biobank to identify a subtype of asthma enriched for patients with high treatment burden and/or worse outcomes. Our findings support the role of known asthma genes, highlighting genetic risk variants with stronger effect in these groups of patients.
ERJ Open Res ·
Smith (last) · Satia (6th of 9)
This trial suggests that the antitussive action of low-dose morphine may be a consequence of modulation of noxious airway sensations and provides the first objective evidence of its efficacy in RCC patients reporting a clinical response.
ERJ Open Res ·
Chalmers (12th of 14)
https://bit.ly/3NYVAM3.
ERJ Open Res ·
Brusselle (18th of 66)
Alongside more experience of treating SA, SA specialists have increased awareness of multimorbidity and better resources to manage it. However, access to MDTs remains a significant gap for both SA specialists and general respiratory physicians.
Chest ·
Chalmers (last)
To understand the role of the microbiome in asthma, microbiome data must be integrated with other so-called omic approaches such as proteomics. Recent studies have used a multiomic approach to investigate the microbiome and host interaction as well as identifying asthma endotypes and potential therapeutic targets.
Pediatr Res ·
Chung (7th of 9)
The prevalence of pediatric asthma exacerbations (AEs) has risen alongside climate change, yet how climate change modifies these exposures to raise pediatric AEs remains unclear. This review synthesizes epidemiological and mechanistic evidence on the contribution of air pollution, temperature, and relative humidity (RH) to pediatric AEs under climate change, drawing on a narrative search of PubMed and Web of Science
ESC Heart Fail · · Title only, no abstract
Guazzi (9th of 19)
No abstract on PubMed; see the source.
Pulm Ther ·
Bel (11th of 14)
This large observational study with up to 6 years of follow-up found no increased malignancy risk with benralizumab versus other therapies in patients with severe asthma.
Ther Adv Respir Dis ·
Chalmers (last)
BackgroundBronchiectasis is increasingly recognized as an inflammatory disease in which "disease activity" is not fully captured by radiology or composite severity scores. Although sputum neutrophil elastase (NE) activity is a validated biomarker, the prognostic value of segment-specific NE activity in bronchial lavage fluid (BLF) remains limited.ObjectivesTo evaluate NE activity in BLF collected from affected bronch
Acta Cardiol ·
Delcroix (11th of 28)
LBMT with FlowTrieverachieved rapid hemodynamic improvement and high technical success in selected patients. Careful selection and operator experience are essential.
Chest ·
Ghofrani (50th of 56)
gov.
Pulm Circ ·
Humbert (10th of 14) · Kovacs (9th of 14)
Noncommunicable diseases (NCDs) are on the rise in sub-Saharan Africa (SSA), with cardiovascular NCD accounting for most deaths. Pulmonary hypertension (PH) is a highly morbid NCD; however, contemporary prevalence data are lacking.
Lancet Respir Med ·
Jackson (last)
[Abstract not available]
Thorax ·
Vestbo (first)
[Abstract not available]
Acta Cardiol ·
Guazzi (7th of 8)
In subjects with dyspnoea, systemic inflammation is linked to increased adiposity and lower exercise capacity because of impaired right ventricular reserve.
COPD ·
Neder (5th of 11) · O'Donnell (last) · Ryerson (7th of 11)
Long-term smokers with persistent dyspnoea and exercise intolerance, who are at risk for COPD, require careful clinical assessment. However, many such individuals have only minor abnormalities on spirometry, and it is not known if various additional tests of small airways dysfunction (SAD) or pulmonary microvascular deficits, offer added clinical value.
ERJ Open Res ·
Chalmers (first)
A small sample size with eosinophil counts predominantly <300 cells·µLand imbalances at baseline limit interpretation of data on clinical outcomes following benralizumab treatment. Adequately powered randomised trials are needed in the population of interest.
ERJ Open Res ·
Chung (2nd of 7)
Although general practitioners and pulmonologists recognise their role in assessing, managing and educating patients about air pollution exposure, their perception of this role and competencies within it indicate the need for educational support translating to impactful practice.
ERJ Open Res ·
Neder (last)
https://bit.ly/42o9B9A.
ERJ Open Res ·
Smith (17th of 19) · Satia (last)
Guideline-based therapy improves objective and subjective cough outcomes; however, most patients fail to achieve satisfactory symptom control, highlighting a substantial unmet need for effective treatments for refractory unexplained chronic cough.
World Allergy Organ J ·
Jackson (5th of 6)
Only one-fifth of patients with severe asthma met UK biologic eligibility. Global criteria tripled eligibility and RCT criteria increased it six-fold, with substantial budget implications.
Contemp Clin Trials Commun ·
Martinez (7th of 10)
Overall, this study addresses an important gap in HP care by targeting HRQOL and offers a novel non-pharmacologic patient-centered approach to therapy in patients with HP.
J Asthma Allergy ·
Jackson (39th of 147) · Wechsler (34th of 147)
Easier access to biologics for patients with SA, a prerequisite for shorter time-to-initiation, was associated with a greater probability of achieving clinical remission and other favorable asthma outcomes. Initiating biologics earlier in the asthma disease course may help unlock greater therapeutic potential in SA.
Biomedicines ·
Richeldi (last)
The therapeutic goals related to chronic airway diseases are evolving from short-term symptom control toward sustained suppression of disease activity and prevention of future risk. In severe asthma, this shift has been captured by the concept of clinical remission, generally defined by absence of exacerbations, no need for oral corticosteroids, symptom control, and stable or improved lung function.
Nothing in this topic in earlier issues.